As China confronts a twelve-fold surge in pertussis cases — over 470,000 reported in 2024 alone — the country's drug regulator has accepted a priority application for Td5cp, a booster vaccine designed by CanSinoBIO to protect adolescents and adults who have long been left outside the circle of pertussis immunity. The move reflects a quiet but consequential reckoning: that vaccination, long understood as a gift given once in childhood, must be renewed across a lifetime. In accepting this application, China's health establishment is acknowledging both the limits of its past strategy and the shap
CanSinoBIO's Td5cp booster vaccine clears China regulatory hurdle
Pertussis resurgence in China with 470,000+ reported cases in 2024 creates public health risk, particularly for unvaccinated populations.
A twelve-fold surge in cases exposed a gap in China's vaccination strategy
Mark
Why does China suddenly have 470,000 pertussis cases? Did vaccination coverage drop?
Mimi
The source doesn't explain the cause of the surge—just that it happened. But the fact that there's no booster vaccine for people over six suggests immunity is waning in older populations who were vaccinated as children decades ago.
Mark
So this is about people whose childhood shots wore off?
Mimi
Partly, yes. But it's also about a gap in the system. China built its vaccination program around protecting infants and young children. Nobody planned for what happens when those children become teenagers and adults with fading immunity.
Mark
And CanSinoBIO's vaccine is the first to address that?
Mimi
For China, yes. The Td5cp is designed specifically as a booster for ages six and up. It includes five pertussis antigens instead of three, which the company believes gives better protection to older immune systems.
Mark
Why five instead of three? What do the extra two do?
Mimi
The source says the additional antigens are FIM2 and FIM3. The company claims they support stronger protection, but the exact mechanism isn't detailed. The emphasis is on precision—each antigen is individually purified and combined at defined ratios.
Mark
This feels like it's part of something larger than just one vaccine.
Mimi
It is. The government issued a five-year plan in July calling for life-course immunization across the entire population. CanSinoBIO is building a portfolio to match that vision—infant vaccine, adolescent and adult booster. If this one gets approved, it signals the market is moving that direction.
Mark
What happens next?
Mimi
The application is now in formal regulatory review. If approved, the company can commercialize it. The real question is how quickly that happens and whether other manufacturers follow with their own boosters.
The Pulse
- Pertussis, once considered a conquered disease, returned in 2024 with alarming force — 470,000 Chinese cases representing a twelve-fold increase over the prior year.
- The surge exposed a structural gap: China had no approved booster vaccine for anyone over six years old, leaving adolescents and adults with waning or absent protection.
- CanSinoBIO's Td5cp, a five-antigen formulation building on its recently approved infant vaccine, was accepted for Priority Review — a signal that regulators recognize the urgency.
- Seven government agencies issued a five-year plan in mid-2026 calling for life-course immunization, giving CanSinoBIO's strategy official alignment and political momentum.
- If approved, Td5cp would be the first pertussis booster in China targeting older populations, potentially reorienting how the country thinks about immunity across the entire lifespan.
As China confronts a twelve-fold surge in pertussis cases — over 470,000 reported in 2024 alone — the country's drug regulator has accepted a priority application for Td5cp, a booster vaccine designed by CanSinoBIO to protect adolescents and adults who have long been left outside the circle of pertussis immunity. The move reflects a quiet but consequential reckoning: that vaccination, long understood as a gift given once in childhood, must be renewed across a lifetime. In accepting this application, China's health establishment is acknowledging both the limits of its past strategy and the shape of a more complete one.
China's drug regulator has accepted CanSinoBIO's application for Td5cp, a pertussis booster vaccine aimed at adolescents and adults, granting it Priority Review status in recognition of an urgent public health need. The decision arrives against a stark backdrop: pertussis cases in China surpassed 470,000 in 2024, a twelve-fold jump from the year before. The disease, spread through respiratory droplets, can be severe in infants and the elderly — and its resurgence has forced authorities to confront a long-standing gap in China's immunization architecture.
For decades, China's vaccination programs focused on early childhood, leaving older populations without a dedicated pertussis booster. Td5cp is designed to fill that void. It contains five pertussis antigens — three shared with CanSinoBIO's recently approved infant vaccine, Tripecia, plus two additional components believed to strengthen protection in older immune systems. Each antigen is individually purified and combined at precise ratios, an approach the company says ensures batch-to-batch consistency.
The regulatory moment is inseparable from a broader policy shift. In July 2026, seven Chinese government agencies jointly released a five-year disease prevention plan explicitly calling for life-course immunization across the entire population — not just children. CanSinoBIO's expanding portfolio, spanning infancy through adulthood, maps directly onto that ambition.
Should Td5cp receive approval, it would be the first vaccine in China specifically designed to restore pertussis immunity in older age groups — a milestone that could prompt competitors to follow and encourage health authorities to reimagine what it means to keep a population protected across a full human lifetime.
China's drug regulator has cleared the way for CanSinoBIO to pursue approval of a new pertussis booster vaccine designed for adolescents and adults—a move that arrives as the country grapples with a dramatic resurgence of the disease. The National Medical Products Administration accepted the company's application for Td5cp, a five-component vaccine combining tetanus, reduced diphtheria, and acellular pertussis antigens, on a priority track that signals the regulator's recognition of an urgent public health need.
The timing reflects a crisis in plain numbers. Pertussis cases reported across China exceeded 470,000 in 2024, a staggering twelve-fold jump from the previous year. The disease, caused by the bacterium Bordetella pertussis, spreads through respiratory droplets and can be severe, particularly in infants and the elderly. For decades, pertussis seemed like a problem solved by vaccination, but the recent surge has forced health authorities to reckon with gaps in China's immunization strategy—specifically, the absence of a dedicated booster vaccine for anyone six years old and above.
CanSinoBIO is positioning Td5cp to fill that gap. The vaccine contains five distinct pertussis antigens: three that appear in the company's recently approved infant formulation (Tripecia, cleared in April 2026) plus two additional components, FIM2 and FIM3, that the company believes will strengthen protection in older populations. Each antigen is individually purified and combined at precise ratios, an approach the company says ensures consistent quality across batches. The regulatory acceptance moves the candidate into formal review, a necessary step before the company can begin selling it in China.
The broader context matters. In July 2026, seven Chinese government agencies—including the National Disease Control and Prevention Administration and the National Development and Reform Commission—issued a five-year disease prevention plan that explicitly calls for a life-course immunization strategy reaching the entire population. That language signals official commitment to vaccination across all ages, not just children. CanSinoBIO's strategy aligns neatly with this directive: the company is building a portfolio of pertussis vaccines spanning infancy through adulthood, each tailored to the immune needs of its target age group.
What makes this moment significant is not just the acceptance of one application, but what it represents about China's vaccine landscape. For years, the country's immunization programs focused heavily on childhood vaccination. The pertussis surge has exposed the vulnerability of that approach—a population of adolescents and adults with waning immunity or no booster protection. CanSinoBIO's Td5cp, if approved, would be the first vaccine in China specifically designed to address that population. The company's success here could reshape how Chinese health authorities think about maintaining immunity across the lifespan, and it may encourage competitors to develop similar products. The regulatory review process now underway will determine whether this vaccine reaches the market, and how quickly.
Notable Quotes
The resurgence has increased attention on booster immunisation in adolescents and adults, particularly as China has lacked a dedicated pertussis-containing booster vaccine for people aged six years and above.— CanSinoBIO
Want the full story?
Read the original at BioSpectrum Asia ↗
Health & Medicine